Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 29, 2023
Product Development

Aug. 29 Quick Takes: Phase III miss in DMD for FibroGen

Plus: Expanded label for BMS’s Reblozyl, Apellis restructuring and updates from Inhibrx, CEPI, iCamuno, Regeneron, Nevia  
BioCentury | Jul 1, 2021
Finance

June 30 Quick Takes: Beam looks to complement Apellis; plus Intellia, Aerovate, Hutchmed, Spero-Pfizer and more

Beam Therapeutics Inc. (NASDAQ:BEAM) unveiled a five-year partnership with Apellis Pharmaceuticals Inc. (NASDAQ:APLS) to collaborate on up to six research programs against complement system targets,
BioCentury | Jun 5, 2021
Targets & Mechanisms

Going beyond genetic medicines for muscular dystrophy

Muscular dystrophy programs in the clinic cover not only a range of muscle mechanisms but also anti-fibrotic and anti-inflammation ones
BioCentury | Jun 11, 2020
Product Development

J&J picks up pace for Warp Speed COVID-19 vaccine

Corning to produce glass packaging for countermeasures; plus progress on host-targeted therapies
BioCentury | Jan 25, 2020
Emerging Company Profile

Aluda: targeting the fundamentals

Aluda begins to unveil pipeline, starting with first-in-class anti-VIM program for fibrosis
BioCentury | Aug 26, 2019
Company News

FibroGen’s Neff passes away

BioCentury | Jul 20, 2018
Financial News

RNAi company OliX lists in Korea

Items per page:
1 - 10 of 105